TIDMDPH
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Millennium International Management
LP
(b) Owner or controller of interests
and short positions disclosed, if
different from 1(a): The naming of
nominee or vehicle companies is
insufficient. For a trust, the
trustee(s), settlor and beneficiaries
must be named.
(c) Name of offeror/offeree in Dechra Pharmaceuticals plc
relation to whose relevant securities
this form relates: Use a separate
form for each offeror/offeree
(d) If an exempt fund manager
connected with an offeror/offeree,
state this and specify identity of
offeror/offeree:
(e) Date position held/dealing 15(th) January 2024
undertaken: For an opening position
disclosure, state the latest
practicable date prior to the
disclosure
(f) In addition to the company in No
1(c) above, is the discloser making
disclosures in respect of any other
party to the offer? If it is a cash
offer or possible cash offer, state
"N/A"
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
Class of relevant security: 1p ordinary (GB0009633180)
Interests Short positions
Number % Number %
(1) Relevant securities owned
and/or controlled: - - - -
(2) Cash-settled derivatives: 1,842,274 1.617% 5,107 0.004%
(3) Stock-settled derivatives
(including options) and
agreements to purchase/sell: - - - -
TOTAL: 1,842,274 1.617% 5,107 0.004%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors'
and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant
percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchase/sale Number of Price per unit
security securities (GBP)
(b) Cash-settled derivative transactions
Nature of dealing
e.g. opening/closing
a long/short
position, Price
Class of Product increasing/reducing Number of per
relevant description a long/short reference unit
security e.g. CFD position securities (GBP)
Increasing a long
GB0009633180 Equity Swap position 180,737 38.66
Increasing a long
GB0009633180 Equity Swap position 300,000 38.66
Increasing a long
GB0009633180 Equity Swap position 1,134 38.67
Increasing a long
GB0009633180 Equity Swap position 642 38.67
Increasing a long
GB0009633180 Equity Swap position 2,337 38.67
Increasing a long
GB0009633180 Equity Swap position 36 38.68
Reducing a long
GB0009633180 Equity Swap position 669 38.66
(c) Stock-settled derivative transactions (including
options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type e.g. Expiry Option
relevant description purchasing, securities price American, date money
security e.g. call selling, to which per European paid/
option varying option unit etc. received
etc. relates per
unit
(ii) Exercise
Class of Product Exercising/ Number of Exercise
relevant description exercised securities price per
security e.g. call against unit
option
(d) Other dealings (including subscribing for new
securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or
understanding, formal or informal, relating to relevant securities which may
be an inducement to deal or refrain from dealing entered into by the person
making the disclosure and any party to the offer or any person acting in
concert with a party to the offer: Irrevocable commitments and letters of
intent should not be included. If there are no such agreements, arrangements
or understandings, state "none"
NONE
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding, formal or informal,
between the person making the disclosure and any other person relating to: (i)
the voting rights of any relevant securities under any option; or (ii) the
voting rights or future acquisition or disposal of any relevant securities to
which any derivative is referenced: If there are no such agreements,
arrangements or understandings, state "none"
NONE
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 16(th) January 2024
Contact name: Stephen Glasper
Telephone number: +44 203 398 2166
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240116740817/en/
CONTACT:
Millennium Partners, L.P.
SOURCE: Millennium Partners, L.P.
Copyright Business Wire 2024
(END) Dow Jones Newswires
January 16, 2024 10:25 ET (15:25 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Dec 2023 to Dec 2024
